NewsHK
Specialty pharma's consolidation cycle produced a clean result on August 28. Crinetics Pharmaceuticals, Inc.
(Nasdaq: CRNX) brought its pending merger with Vertex Pharmaceuticals Incorporated to a shareholder vote, and the margin left little to interpret: 79,240,098 votes for adoption of the merger agreement, 13,618 against, and 10,915 abstaining, with 79,264,631 of 106,095,205 eligible shares represented.
The approval satisfies what Crinetics described as the final outstanding condition to closing, and the company anticipates the transaction will close on or about September 1, 2026.
The structure of the vote The merger agreement, dated July 6, 2026, calls for Vertex's wholly owned subsidiary Clark Merger Sub, Inc.
Keep reading